Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch

Dow Jones

Aug 15

By Nicholas G. Miller

Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.

The stock is up 10% to $7.23 and is up 44% over the past 12 months.

The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.

Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.

Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

August 14, 2025 14:48 ET (18:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559962969"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559962969\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559962969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 02:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559962969","market":"sh","top_or_hot":-1,"title":"Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-15 02:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABEO","symbol_name":"Abeona Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2559962969","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559962969","pubTimestamp":1755197280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.The stock is up 10% to $7.23 and is up 44% over the past 12 months.The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABEO":"Abeona Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Abeona Therapeutics股价因第二季度净值上涨和药物上市而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":1},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n\n\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n\n\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n\n\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n\n\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 14:48 ET (18:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}